Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy

【24h】

Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy

机译：激素受体阳性HER2阴性转移性乳腺癌在靶向治疗时期的血管血米和大使治疗模式

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：激素受体阳性HER2阴性转移性乳腺癌在靶向治疗时期的血管血米和大使治疗模式
2. Long-term remission of hormone receptor-positive/HER2-positive metastatic breast cancer due to combined treatment with everolimus/trastuzumab/exemestane: A case report [J] . Wang Jian, Sun Chunxiao, Huang Xiang, Oncology letters . 2017,第2aPta1期

机译：由于与Everolimus / Trastuzumab / Exemestane组合治疗，激素受体阳性/ HER2阳性转移性乳腺癌的长期缓解：案例报告
3. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study [J] . Clinton Yam, Francisco J. Esteva, Miral M. Patel, Investigational new drugs. . 2019,第2期

机译：二甲双胍，血症司和20名在超重和肥胖绝经后期转移，激素受体阳性，HER2阴性乳腺癌患者中的疗效和安全性的疗效和安全性：II期研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Treatment Interruption and Discontinuation of Hormone Therapy in Hormone Receptor-Positive Breast Cancer Patients [D] . Mao, Daqin . 2020

机译：激素受体阳性乳腺癌患者中的治疗中断与激素治疗中的中断和停止
6. Exemestane and Everolimus combination treatment of hormone receptor positive HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity efficacy and safety [O] . Ferdinando Riccardi, Giuseppe Colantuoni, Anna Diana, -1

机译：依西美坦和依维莫司联合治疗激素受体阳性HER2阴性转移性乳腺癌：对坎帕尼亚地区（意大利南部）的9个癌症中心的回顾性研究重点是活性疗效和安全性
7. PCN23 Comparison Between Everolimus (Afinitor®) and Chemotherapy Agents (Capecitabine, Docetaxel and Doxorubicin) for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2–) Advanced or Metastatic Breast Cancer [O] . Vieira J., Chandiwana D., Taylor M., 2013

机译：依维莫司（Afinitor®）与化学治疗剂（卡培他滨，多西他赛和阿霉素）治疗激素受体阳性（HR +）HER2阴性（HER2–）晚期或转移性乳腺癌的PCN23比较

Patterns of treatment with everolimus and exemestane in hormone receptor positive HER2 negative metastatic breast cancer in the era of targeted therapy

著录项

引文网络

相似文献

相关主题

期刊订阅